We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




World’s First Smart, Refillable and Fully Implantable Medical Device Delivers Medicine Directly to the Brain

By HospiMedica International staff writers
Posted on 02 Oct 2023

The blood-brain barrier is a strong defense mechanism that safeguards the brain from harmful substances while still letting vital nutrients in. More...

Made up of specialized endothelial cells, tight junctions, and astrocytes, this barrier effectively blocks over 95% of drugs delivered through the bloodstream or in pill form, making it hard to treat a range of brain-related conditions. Now, an implantable drug delivery device capable of circumventing the blood-brain barrier could revolutionize brain treatment.

CraniUS LLC’s (Baltimore, MD, USA) NeuroPASS device is a groundbreaking solution that aims to overcome the obstacles created by the blood-brain barrier. It is the world’s first fully implantable, wireless medical device that enables chronic and direct medicine delivery to the brain. It is easily refillable, rechargeable from a distance, and can remain unnoticed under the skin in the skull. The device employs catheters driven by a pump that go into the brain tissue, allowing for controlled infusion of medications. NeuroPASS uses a technique called convection-enhanced delivery (CED), which utilizes pressure differences to accurately spread medications throughout the targeted brain area, surpassing the limitations of passive diffusion. The device is versatile, with applications for a variety of brain-related conditions including neurodegenerative diseases and brain tumors.

A preliminary study has validated the device's capability to achieve meaningful medication flow and distribution beyond the initial catheter pathway by delivering gadolinium through catheters with NeuroPASS. This marks the first time that a device has been successfully implanted in the skull area to allow direct brain access for successful convection. This achievement clears the way for CraniUS to proceed to an FDA pre-clinical study, and the company aims to secure IND approval for initial human trials by the close of 2024.

"I could not be any prouder of our talented team and the findings of this recent breakthrough study,” said Mike Maglin, CEO of CraniUS. “Being able to show that our patented device is both safe and effective in achieving convection in large animals with similar brains to humans represents a tremendous culmination of hard work and determination by our team."

Related Links:
CraniUS LLC


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.